Market Place
Sourcing Support
Bold`s BOLD-100 Shows Safety, Efficacy In Biliary Tract, Gastric Cancers
03 Jun 2024 //
PR NEWSWIRE
BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024
05 Apr 2024 //
PR NEWSWIRE
Bold Therapeutics Announces Positive Phase 2 Efficacy Results for BOLD-100
22 Jan 2024 //
PR NEWSWIRE
Bold Therapeutics Presents Positive Phase 2 Results for BOLD-100
06 Jun 2023 //
PR NEWSWIRE
Bold Therapeutics to Present Positive Interim Gastric and Biliary Tract Cancer Results
01 Jun 2023 //
PR NEWSWIRE
Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Data for BOLD-100
18 Apr 2023 //
PR NEWSWIRE
Bold to Present Phase 2 Metastatic Colorectal Cancer Data at AACR 2023
13 Apr 2023 //
PR NEWSWIRE
Bold Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Conferences
14 Oct 2022 //
PRNEWSWIRE
Bold Therapeutics` BOLD-100 Early mCRC Data to be Showcased at 2022 MMGRC
24 Jun 2022 //
PRNEWSWIRE
Bold Therapeutics to Present at Bio Korea 2022
10 May 2022 //
PRNEWSWIRE
BOLD-100`s Broad Potential Featured at the AACR Annual Meeting 2022
06 Apr 2022 //
PRNEWSWIRE
Bold Therapeutics Extends South Korea Option Agreement for BOLD-100
13 Jan 2022 //
PRNEWSWIRE
BOLD-100 Exhibits Potent Anti-Tumor Activity in Validated I/O In Vivo Models
16 Sep 2021 //
PRNEWSWIRE
Bold Receives FDA Clearance to Add U.S. Sites for BOLD-100 trial
07 Jul 2021 //
PR NEWSWIRE
Bold Receives FDA Clearance to Add Sites for Phase 1b / 2a Trial of BOLD-100
07 Jul 2021 //
PR NEWSWIRE
Bold Receives FDA Clearance to Add U.S. Sites for BOLD-100 trial
07 Jul 2021 //
PR NEWSWIRE
FDA Grants Bold Therapeutics` BOLD-100 an Orphan Drug Designation (ODD)
11 May 2021 //
PRNEWSWIRE
Bold Therapeutics` BOLD-100 Effective In Vitro Against COVID-19 Variants
16 Apr 2021 //
PRNEWSWIRE
Bold Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials
06 Jan 2021 //
PRNEWSWIRE
Bold Therapeutics Successfully Trial of First-in-Class Anti-Cancer BOLD-100
09 Oct 2020 //
PRNEWSWIRE
BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2
17 Aug 2020 //
PRNEWSWIRE
Bold Therapeutics Executes Option Agreement for Exclusive DevP BOLD-100
27 May 2020 //
PRNEWSWIRE
Bold Therapeutics and the University of Ottawa Initiate Research Partnership
15 Apr 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.